Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab + either cisplatin or carboplatin + gemcitabine versus placebo+ either cisplatin or carboplatin + gemcitabine in approximately 420 participants with locally advanced or metastatic urothelial carcinoma who have not received prior systemic therapy.

Timeline

Start

2019-05-29

Primary completion

2027-06-30

Completion

2027-10-21

Publications

• Huang H, Dai Z, Jiang Z, Li X, Ma L, Ji Z, Fan X. Anti-PD-1 immunotherapy for the treatment of metastatic urothelial carcinoma in a kidney transplant recipient: a case report. BMC Nephrol. 2024 Oct 31;25(1):390. doi: 10.1186/s12882-024-03825-2.

Drugs

Indications